Caribou Biosciences

10:00 AM - 10:15 AM (EDT), Wednesday, October 23, 2019 ・ 2nd Floor
Caribou Biosciences is a leading company in CRISPR genome editing founded by pioneers of CRISPR-Cas9 biology. We are using a next-generation gene editing technology to develop a pipeline of off-the-shelf CAR-T cell therapies for the treatment of cancer. We are also using gene editing to develop novel microbiome based therapies. Our lead product, CB-010, is targeted to CD19 and is being developed to treat selected hematological malignancies. The company is located in Berkeley, California.
Company Type:
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2011
Main Therapeutic Focus:
Lead Product in Development:
CB010
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3